Danatlas Pharmaceuticals

Explore the latest insights on Danatlas Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Danatlas Pharmaceuticals’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals announced that the first subject has been enrolled and dosed in the Phase II clinical study of DAT‑2645, the company's independently developed Class 1 innovative drug, at the…

October 6, 2026